Navigation Links
Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
Date:10/27/2009

Phase II study results in type 2 diabetes patients with nonalcoholic fatty liver disease, supports INT-747's potential as a novel therapeutic across a range of chronic liver diseases. We intend to present the complete data set from the study at an appropriate scientific meeting in 2010."

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "This study involved more than 30 centers in eight countries and has given us a better understanding of the needs of PBC patients, as well as a good working relationship with the hepatologists looking after them across North America and Europe. With this PBC network in place, we are well positioned to conduct a Phase III program. We intend to request an End of Phase II Meeting with FDA to review the results and plans for a Phase III program."

About INT-747 (first-in-class FXR agonist)

INT-747 is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid (CDCA), the natural endogenous FXR agonist. INT-747 is formulated as an orally bioavailable drug given once daily. Bile acid signaling through FXR has been shown to regulate the regenerative properties of the liver and, in numerous animal models of liver disease, INT-747 treatment prevents, and even reverses, liver damage caused by progressive fibrosis (scarring). FXR is also expressed in the intestine and kidney and INT-747 exhibits similar protective antifibrotic effects in models of inflammatory bowel disease and diabetic nephropathy.

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Intercept's le
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
2. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
3. BioMarin Acquires Huxley Pharmaceuticals, Inc.
4. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
5. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
7. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
8. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
9. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific has ... Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, ... investigating vagus nerve stimulation (VNS) for the treatment ... Professor of Therapeutics and Cardiology and Director of ... de la Sante et de la Recherche Medicale ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... Jan. 25, 2012  Amorcyte, LLC, a NeoStem, Inc. ... announces the enrollment of the first patient in ... myocardial infarction. The study is a multicenter, randomized, ... and efficacy of infarct-related artery infusion of AMR-001, ...
... hosting a free webinar on the upcoming changes to the ... and is intended to address the growing number of questions ... (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ) "We,ll do ... the current status and upcoming changes, as well as insight ...
Cached Medicine Technology:Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
(Date:8/30/2014)... OH (PRWEB) August 30, 2014 United Theological ... first fully online degree, the Master of Theological Studies (MTS). ... in 2-3 years, is designed for students who wish to ... their understanding and capacity to serve the Church and community. ... degree, but now they can attend classes from any location ...
(Date:8/30/2014)... Daily Gossip reveals in its recently published ... method created by Sarah Summer, who can perfectly understand what ... this new program actually had to deal with this disorder, ... able to access it, in an all-natural holistic cure program. ... an effective cure for yeast infection. The author of this ...
(Date:8/30/2014)... August 30, 2014 The establishment ... planet has been one of the main strategies ... create a positive impact around the world. , ... with top trained executives and trainers deliver L. ... worldwide. Vital statistics demonstrate that significant reduction ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team of ... is pleased to report having saved a client $67,100 ... many cases where Hastings and Hastings has tailored its ... greater portion of their settlement or recovery. The firm ... solution for Arizona car accident victims is achievable through ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... associated with an increased risk of colorectal cancer, according to ... of Medicine of Yeshiva University. The findings, observed in ... edition of the British Journal of Cancer . ... the third most commonly diagnosed cancer and the third leading ...
... like bone. For the most part, it acts like bone., ... researchers have used a 3D printer to create a bone-like ... dental work, and to deliver medicine for treating osteoporosis. Paired ... bone to grow on and ultimately dissolves with no apparent ...
... News) -- Men are less willing than women to be ... rates, a new study shows. Researchers conducted a telephone ... and San Juan, Puerto Rico, who answered questions from the ... to 59, and 35 percent of them were men. ...
... research at SRI International, scientists evaluating new drug targets ... a target that could rapidly eliminate infections and potentially ... protein called DNA gyrase B, found in bacteria that ... consisting of two subunits: gyrase A and gyrase B. ...
... A University of Kentucky faculty member is a contributing ... a common solvent chemical and Parkinson,s disease. Dr. Franca ... researchers from across the U.S. on a paper recently ... novel study looked at a cohort of human twins ...
... , TUESDAY, Nov. 29 (HealthDay News) -- A new study is ... one topic: sex. The research in college-age participants suggests that ... subject crosses their mind an average of only about 19 times ... The results seem to disprove the popular notion that men think ...
Cached Medicine News:Health News:High blood sugar levels in older women linked to colorectal cancer 2Health News:Men More Likely to Skip Cancer Screenings: Study 2Health News:Study demonstrates a connection between a common chemical and Parkinson's disease 2Health News:Do Men Think About Sex All the Time? Maybe Not 2
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
... the need for makeshift, modified nebulizer setups ... time gathering parts when your patient is ... deliver the utmost in Heliox rescue therapy. ... fast becoming the standard of care in ...
Medicine Products: